Recursion’s REC-994 Passes Phase II, But Needs To Find Right Dosage, Endpoints For Next Study

The study, in cerebral cavernous malformation (CCM), hit the safety primary endpoint and showed signals in efficacy, but analysts pointed out that the bar for success in the disease remains unclear.